According to filings with the U.S. Securities and Exchange Commission, Endogenex is raising $18,325,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stacey Pugh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Endogenex
Endogenex is a clinical stage company, that in partnership with Mayo Clinic, was founded to improve outcomes for people living with Type 2 Diabetes. Endogenex’s focus is on the principle that effective treatment for Type 2 Diabetes can extend beyond pharmacologic options and reset the disease process. Through development of the endoscopic ReCET Procedure and the novel application of non-thermal pulsed electric fields, Endogenex is striving to help people with Type 2 Diabetes regain control of their blood glucose levels. Through a partnership with Mayo Clinic, Endogenex, has developed the ReCET Procedure, based on the principle of metabolic change through Intestinal Cellular Regeneration (ICR). The ReCET Procedure is investigational and under evaluation in clinical studies. The procedure is designed to promote better blood glucose control and potentially slow the progression of Type 2 Diabetes. 

To learn more about Endogenex, visit http://www.endogenex.com/

Contact:
Stacey Pugh, Chief Executive Officer
651-341-3805

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.